Celecoxib

Generic Name
Celecoxib
Brand Names
Celebrex, Elyxyb, Seglentis
Drug Type
Small Molecule
Chemical Formula
C17H14F3N3O2S
CAS Number
169590-42-5
Unique Ingredient Identifier
JCX84Q7J1L
Background

Celecoxib, a selective cyclooxygenase-2 (COX-2) inhibitor, is a nonsteroidal anti-inflammatory drug (NSAID) which is known for its decreased risk of causing gastrointestinal bleeding compared to other NSAIDS. It is used to manage symptoms of various types of arthritis pain and in familial adenomatous polyposis (FAP) to reduce precancerous polyps in the colon...

Indication

Celecoxib is indicated for symptomatic treatment of adult osteoarthritis (OA) and adult rheumatoid arthritis (RA). Celecoxib is not a substitute for aspirin for cardiovascular event prophylaxis.
...

Associated Conditions
Acute Pain, Ankylosing Spondylitis (AS), Osteoarthritis (OA), Primary Dysmenorrhoea, Rheumatoid Arthritis, Rheumatoid Arthritis, Juvenile, Severe Acute Pain
Associated Therapies
-
Clinical Trials
Related News

Radiation Therapy Plus Celecoxib, Fluorouracil, and Cisplatin in Patients With Locally Advanced Cervical Cancer

Phase 1
Completed
Conditions
Cervical Cancer
First Posted Date
2003-01-27
Last Posted Date
2013-11-19
Lead Sponsor
Radiation Therapy Oncology Group
Target Recruit Count
84
Registration Number
NCT00023660
Locations
🇺🇸

Akron General Medical Center, Akron, Ohio, United States

🇺🇸

Akron City Hospital - Summa Health System, Akron, Ohio, United States

🇺🇸

Western Pennsylvania Hospital, Pittsburgh, Pennsylvania, United States

and more 33 locations

Temozolomide, Thalidomide, and Celecoxib Following Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme

Phase 2
Completed
Conditions
Brain and Central Nervous System Tumors
First Posted Date
2003-01-27
Last Posted Date
2017-07-11
Lead Sponsor
Dana-Farber Cancer Institute
Registration Number
NCT00047294
Locations
🇺🇸

Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States

🇺🇸

Brigham and Women's Hospital, Boston, Massachusetts, United States

🇺🇸

Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute, Boston, Massachusetts, United States

and more 1 locations

Celecoxib to Treat Macular Degeneration in Patients Receiving Photodynamic Therapy

Phase 2
Completed
Conditions
Macular Degeneration
First Posted Date
2002-08-12
Last Posted Date
2008-03-04
Lead Sponsor
National Eye Institute (NEI)
Target Recruit Count
60
Registration Number
NCT00043680
Locations
🇺🇸

National Eye Institute (NEI), Bethesda, Maryland, United States

Phase I Study of Gene Induction Mediated by Sequential Decitabine/Depsipeptide Infusion With or Without Concurrent Celecoxib in Subjects With Pulmonary and Pleural Malignancies

First Posted Date
2002-05-22
Last Posted Date
2019-09-30
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
34
Registration Number
NCT00037817
Locations
🇺🇸

National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

For Prevention of Diarrhea in Patients Diagnosed With Metastatic Colorectal Cancer Treated With Chemotherapy

Phase 2
Terminated
Conditions
Neoplasm Metastasis
Colorectal Neoplasms
First Posted Date
2002-05-17
Last Posted Date
2008-09-29
Lead Sponsor
Pfizer
Target Recruit Count
212
Registration Number
NCT00037180
Locations
🇺🇸

Pfizer Investigational Site, Milwaukee, Wisconsin, United States

Chemoprevention of Oral Premalignant Lesions

Phase 2
Completed
Conditions
Precancerous Conditions
First Posted Date
2002-05-09
Last Posted Date
2008-09-29
Lead Sponsor
Pfizer
Target Recruit Count
42
Registration Number
NCT00036283
Locations
🇺🇸

Pfizer Investigational Site, Seattle, Washington, United States

Glucosamine/Chondroitin Arthritis Intervention Trial (GAIT)

Phase 3
Completed
Conditions
Osteoarthritis
First Posted Date
2002-04-08
Last Posted Date
2009-01-21
Lead Sponsor
US Department of Veterans Affairs
Target Recruit Count
1588
Registration Number
NCT00032890
Locations
🇺🇸

*Indiana University School of Medicine, Indianapolis, Indiana, United States

🇺🇸

*Case Western Reserve University, Beachwood, Ohio, United States

🇺🇸

Arthritis Consultation Center, Dallas, Texas, United States

and more 13 locations

Anti-Inflammatory Treatment for Age-Associated Memory Impairment: A Double-Blind Placebo-Controlled Trial

Phase 3
Completed
Conditions
Memory Disorders
First Posted Date
2001-01-24
Last Posted Date
2020-03-02
Lead Sponsor
University of California, Los Angeles
Registration Number
NCT00009230
Locations
🇺🇸

UCLA Neuropsychiatric Institute, Los Angeles, California, United States

Celebrex for Pain Relief After Oral Surgery

Phase 2
Completed
Conditions
Facial Pain
First Posted Date
2000-09-28
Last Posted Date
2008-03-04
Lead Sponsor
National Institute of Dental and Craniofacial Research (NIDCR)
Target Recruit Count
120
Registration Number
NCT00006299
Locations
🇺🇸

National Institute of Dental And Craniofacial Research (NIDCR), Bethesda, Maryland, United States

Study of Etanercept and Celecoxib to Treat Temporomandibular Disorders (Painful Joint Conditions)

Phase 2
Completed
Conditions
Temporomandibular Joint Disorder
First Posted Date
2000-01-19
Last Posted Date
2008-03-04
Lead Sponsor
National Institute of Dental and Craniofacial Research (NIDCR)
Target Recruit Count
150
Registration Number
NCT00001955
Locations
🇺🇸

National Institute of Dental And Craniofacial Research (NIDCR), Bethesda, Maryland, United States

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy